Miso Kim

5.0k total citations
87 papers, 1.7k citations indexed

About

Miso Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Miso Kim has authored 87 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Miso Kim's work include Cancer Immunotherapy and Biomarkers (26 papers), Lung Cancer Treatments and Mutations (22 papers) and Lung Cancer Research Studies (15 papers). Miso Kim is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Lung Cancer Treatments and Mutations (22 papers) and Lung Cancer Research Studies (15 papers). Miso Kim collaborates with scholars based in South Korea, United States and Ethiopia. Miso Kim's co-authors include Bhumsuk Keam, Dae Seog Heo, Tae Min Kim, Dong‐Wan Kim, Yoon Kyung Jeon, Chan-Young Ock, Jong Seok Lee, Yu Jung Kim, Se Hyun Kim and Sehui Kim and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Miso Kim

83 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miso Kim South Korea	25	1.2k	710	292	276	248	87	1.7k
Ruth Vera Spain	24	1.3k 1.1×	394 0.6×	252 0.9×	347 1.3×	357 1.4×	102	1.8k
Aurélie Bertaut France	24	838 0.7×	590 0.8×	357 1.2×	303 1.1×	330 1.3×	105	1.8k
Andrew Dean Australia	17	1.1k 0.9×	694 1.0×	262 0.9×	124 0.4×	198 0.8×	104	1.6k
Olivier Dubreuil France	15	932 0.8×	498 0.7×	310 1.1×	259 0.9×	378 1.5×	56	1.6k
Leila Khoja United Kingdom	20	1.7k 1.4×	612 0.9×	416 1.4×	403 1.5×	159 0.6×	50	2.1k
Jerome H. Goldschmidt United States	16	1.3k 1.1×	1.0k 1.5×	356 1.2×	241 0.9×	132 0.5×	68	1.9k
Édith Borcoman France	17	948 0.8×	419 0.6×	239 0.8×	281 1.0×	150 0.6×	50	1.3k
Josiane Otto France	20	1.1k 0.9×	906 1.3×	228 0.8×	115 0.4×	175 0.7×	59	1.6k
Michael Ong Canada	17	1.1k 0.9×	451 0.6×	362 1.2×	247 0.9×	562 2.3×	89	1.8k
Diégo Tosi France	20	621 0.5×	386 0.5×	365 1.3×	201 0.7×	142 0.6×	73	1.4k

Countries citing papers authored by Miso Kim

Since Specialization

Citations

This map shows the geographic impact of Miso Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miso Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miso Kim more than expected).

Fields of papers citing papers by Miso Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miso Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miso Kim. The network helps show where Miso Kim may publish in the future.

Co-authorship network of co-authors of Miso Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Miso Kim. A scholar is included among the top collaborators of Miso Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miso Kim. Miso Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Changhee, Rathana Kim, Jae Moon Bae, et al.. (2025). Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications. ESMO Open. 10(1). 104097–104097. 1 indexed citations

Lim, Yoojoo, Chan‐Young Ock, Jeonghwan Youk, et al.. (2025). Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma. Journal of Thoracic Disease. 17(7). 4409–4419.

Youk, Jeonghwan, Yoojoo Lim, Hwang‐Phill Kim, et al.. (2024). Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non–Small Cell Lung Cancer. Cancer Research and Treatment. 56(3). 765–773. 5 indexed citations

Koh, Jaemoon, Tae Min Kim, Jeonghwan Youk, et al.. (2024). Transcriptomic Heterogeneity of EGFR -Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer. Clinical Cancer Research. 30(20). 4729–4742. 5 indexed citations

Kim, Yu Jung, Soyeon Kim, Tae Min Kim, et al.. (2024). A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19). Lung Cancer. 194. 107870–107870. 1 indexed citations

Kim, Miso, et al.. (2023). CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells. International Journal of Molecular Sciences. 24(22). 16065–16065. 9 indexed citations

Kim, Miso, Soyeon Kim, Jeemin Yim, et al.. (2023). Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer. Cancer Research and Treatment. 55(4). 1134–1143. 4 indexed citations

Jung, Eun Hee, Se Hyun Kim, Koung Jin Suh, et al.. (2021). Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer. Thoracic Cancer. 12(5). 619–630. 12 indexed citations

Kim, Hong-Sik, Dong‐Wan Kim, Miso Kim, et al.. (2021). Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11). Cancer. 128(4). 778–787. 30 indexed citations

10.

Kim, Miso, Bhumsuk Keam, Chan‐Young Ock, et al.. (2020). Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07. Thoracic Cancer. 11(12). 3482–3489. 19 indexed citations

11.

Yang, Bo Ram, Myoung‐jin Jang, Miso Kim, et al.. (2020). Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients. Cancer Research and Treatment. 53(1). 65–76. 9 indexed citations

12.

Choi, Yeonjoo, Bhumsuk Keam, Miso Kim, et al.. (2019). Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients. Cancer Research and Treatment. 51(4). 1549–1556. 39 indexed citations

13.

Park, Changhee, Bhumsuk Keam, Soon Ho Yoon, et al.. (2019). Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. ESMO Open. 4(6). e000575–e000575. 5 indexed citations

14.

Kim, Se Hyun, Yu Jung Kim, Joo Hyun Lee, et al.. (2018). Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Yonsei Medical Journal. 59(2). 202–202. 7 indexed citations

15.

Yun, Young Ho, Kyoung‐Nam Kim, Jin-Ah Sim, et al.. (2018). Comparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal of futile life-sustaining treatment, passive euthanasia, active euthanasia and physician-assisted suicide): a multicentred cross-sectional survey of Korean patients with cancer, their family caregivers, physicians and the general Korean population. BMJ Open. 8(9). e020519–e020519. 24 indexed citations

16.

Suh, Koung Jin, Ki Hwan Kim, Ja Min Byun, et al.. (2018). Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. The Korean Journal of Internal Medicine. 34(4). 894–901. 1 indexed citations

17.

Byun, Ja Min, Ki Hwan Kim, Miso Kim, et al.. (2017). Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. Leukemia & lymphoma. 58(11). 2624–2632. 9 indexed citations

18.

Ock, Chan-Young, Bhumsuk Keam, Sehui Kim, et al.. (2016). Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research. 22(9). 2261–2270. 201 indexed citations

19.

Kim, Miso, Ja Hyeon Ku, Cheol Kwak, et al.. (2015). Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. PLoS ONE. 10(7). e0133371–e0133371. 7 indexed citations

20.

Kim, Miso, Hyun Chang, Hee Chul Yang, et al.. (2014). Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World Journal of Surgical Oncology. 12(1). 37–37. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact